孔凡铭, 王娜, 谢红霞, 赵璐, 张豆, 张晶, 张丽丽, 陈立伟, 贾英杰. 消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌维持治疗中的临床研究[J]. 中国肿瘤临床, 2023, 50(10): 519-525. DOI: 10.12354/j.issn.1000-8179.2023.20221577
引用本文: 孔凡铭, 王娜, 谢红霞, 赵璐, 张豆, 张晶, 张丽丽, 陈立伟, 贾英杰. 消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌维持治疗中的临床研究[J]. 中国肿瘤临床, 2023, 50(10): 519-525. DOI: 10.12354/j.issn.1000-8179.2023.20221577
shu
Fanming Kong, Na Wang, Hongxia Xie, Lu Zhao, Dou Zhang, Jing Zhang, Lili Zhang, Liwei Chen, Yingjie Jia. A clinical study of Xiaoyan decoction combined with capecitabine and bevacizumab for the maintenance treatment of colorectal cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(10): 519-525. DOI: 10.12354/j.issn.1000-8179.2023.20221577
Citation: Fanming Kong, Na Wang, Hongxia Xie, Lu Zhao, Dou Zhang, Jing Zhang, Lili Zhang, Liwei Chen, Yingjie Jia. A clinical study of Xiaoyan decoction combined with capecitabine and bevacizumab for the maintenance treatment of colorectal cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(10): 519-525. DOI: 10.12354/j.issn.1000-8179.2023.20221577
shu

消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌维持治疗中的临床研究

A clinical study of Xiaoyan decoction combined with capecitabine and bevacizumab for the maintenance treatment of colorectal cancer

    摘要
  • 摘要:
      目的  探讨消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌（colorectal cancer，CRC）维持治疗中的疗效和安全性。
      方法  回顾性选取2016年1月至2021年12月于天津中医药大学第一附属医院接受一线标准化疗后进入维持治疗阶段的晚期CRC患者120例，分为治疗组（消岩汤联合卡培他滨和贝伐珠单抗维持治疗）60例和对照组（卡培他滨和贝伐珠单抗维持治疗）60例。比较两组间的无进展生存期（progression-free survival，PFS），总生存期（overall survival，OS）和安全性。
      结果  两组患者在基线特征方面差异无统计学意义，治疗组显著延长了CRC患者的PFS（10.9个月 vs. 9.2个月，P=0.03），但OS未见显著获益（21.2个月 vs. 19.4个月，P=0.87）。消岩汤可改善患者神疲乏力（P=0.01）、恶心呕吐（P=0.01）、腹胀（P=0.02）的症状，且能减少恶心呕吐（P=0.04）及腹泻（P=0.02）的不良反应。
      结论  消岩汤联合卡培他滨和贝伐珠单抗维持治疗可显著提高晚期CRC患者的PFS，减轻胃肠道系统不良反应且安全性良好。

     

    Abstract:
      Objective  To investigated the efficacy and safety of Xiaoyan decoction combined with capecitabine and bevacizumab for the maintenance treatment in patients with colorectal cancer (CRC).
      Methods  At the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, a retrospective analysis was conducted for 120 advanced CRC patients who had completed first-line standard chemotherapy and entered maintenance therapy from January 2016 to December 2021. The treatment group (n=60) was treated with Xiaoyan decoction plus capecitabine and bevacizumab, whereas the control group (n=60) was treated with capecitabine and bevacizumab. Progression-free survival (PFS), overall survival (OS), and safety were evaluated.
      Results  No significant difference in baseline characteristics was observed between the two groups. The treatment group experienced significantly prolonged PFS (10.9 months vs. 9.2 months, P=0.03), but no significant benefit was seen in OS (21.2 months vs. 19.4 months, P=0.87). Xiaoyan decoction was able to improve the symptoms of fatigue (P=0.01), vomiting (P=0.01), and abdominal distension (P=0.02) and reduce the severity of the adverse reactions of vomiting (P=0.04) and diarrhea (P=0.02).
      Conclusions  Xiaoyan decoction combined with capecitabine and bevacizumab can significantly improve PFS in advanced CRC patients, reduce gastrointestinal adverse reactions, and provide good safety.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回